Last 43 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.43 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 29.13 | — | — | — | — | 62.03 | 38.67 | 12.60 | 33.27 | 13.38 | 123.02 | 16.11 | 21.92 |
| — | — | — | — | — | +363.7% | -68.6% | -21.8% | +51.8% | -42.5% | +2473.1% | +1535.3% | -65.6% | |
| P/B Ratio | 0.93 | 1.45 | 1.34 | 1.12 | 1.14 | 1.22 | 1.54 | 0.82 | 0.78 | 0.69 | 0.99 | 0.88 | 1.00 |
| — | +19.3% | -13.2% | +36.3% | +46.6% | +75.7% | +55.5% | -7.4% | -22.5% | -19.9% | +17.3% | -65.6% | -76.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -855.8% | — | — | — | — | -1495.3% | -743.8% | -415.1% | -1054.1% | -356.8% | -2702.9% | -316.2% | -353.4% |
| — | — | — | — | — | -319.1% | +72.5% | -31.3% | -198.3% | +9.0% | -38483.0% | -445.1% | +41.3% | |
| Operating Margin | -1231.7% | — | — | — | — | -2142.3% | -1030.0% | -579.2% | -1613.2% | -530.9% | -3827.2% | -494.7% | -555.3% |
| — | — | — | — | — | -303.6% | +73.1% | -17.1% | -190.5% | +15.6% | -7043.7% | -660.3% | +37.6% | |
| Net Margin | -1087.4% | — | — | — | — | -2408.8% | -972.4% | -413.6% | -1916.7% | -450.2% | -3852.3% | -502.4% | -762.6% |
| — | — | — | — | — | -435.1% | +74.8% | +17.7% | -151.3% | +13.0% | -16875.5% | -666.9% | +24.4% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -34.0% | -11.7% | -17.4% | -12.4% | -8.0% | -11.1% | -9.3% | -6.6% | -10.6% | -5.7% | -7.5% | -6.7% | -8.4% |
| — | -5.0% | -86.7% | -89.3% | +24.5% | -95.9% | -24.6% | +2.0% | -25.8% | -21.7% | -642.9% | -108.1% | +45.4% | |
| ROA | -30.3% | -10.0% | -15.4% | -11.2% | -7.2% | -10.1% | -8.5% | -5.9% | -9.5% | -5.1% | -6.7% | -6.0% | -7.6% |
| — | +0.9% | -81.6% | -89.8% | +24.4% | -98.1% | -25.8% | +2.4% | -25.7% | -22.4% | -671.5% | -109.6% | +26.3% | |
| ROIC | -47.6% | -43.8% | -34.4% | -18.7% | -14.2% | -13.0% | -12.2% | -11.0% | -10.2% | -7.3% | -7.9% | -7.4% | -6.6% |
| — | -237.9% | -182.1% | -70.5% | -39.3% | -78.7% | -53.5% | -48.1% | -54.3% | -13.1% | -139.6% | -105.5% | +75.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 35.2% YoY to 9.28x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| — | -19.0% | -12.1% | -16.0% | -16.6% | -1.7% | -5.1% | -2.9% | +0.4% | -1.6% | +0.8% | -5.6% | -63.4% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.31 | 9.28 | 9.35 | 15.28 | 14.31 | 14.33 | 14.58 | 14.68 | 13.35 | 14.58 | 14.29 | 15.44 | 14.77 |
| — | -35.2% | -35.9% | +4.1% | +7.2% | -1.7% | +2.0% | -5.0% | -9.6% | +1.4% | +14.3% | +54.8% | +321.5% | |
| Quick Ratio | 14.31 | 9.28 | 9.35 | 15.28 | 14.31 | 14.33 | 14.58 | 14.68 | 13.35 | 14.58 | 14.29 | 15.44 | 14.77 |
| — | -35.2% | -35.9% | +4.1% | +7.2% | -1.7% | +2.0% | -5.0% | -9.6% | +1.4% | +14.3% | +54.8% | +321.5% | |
| Interest Coverage | -2448.68 | -4015.00 | -4329.25 | -3228.40 | -2465.67 | -1621.00 | -2662.67 | -2265.43 | -1513.45 | -1686.13 | -1764.78 | -1676.44 | -1869.38 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonMolecular Partners AG's current P/E is -2.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Molecular Partners AG's current operating margin is -1231.7%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Molecular Partners AG's business trajectory between earnings reports.